Top Markets
Coin of the day
Epigenomics AG Epigenomics AG

Epigenomics AG

ECX
Rang in Aktien #38936
Founded in 1998 and headquartered in Berlin, Germany, Epigenomics AG is a... Founded in 1998 and headquartered in Berlin, Germany, Epigenomics AG is a molecular diagnostics company dedicated to the early detection of cancer through liquid biopsy methods. Its primary offering, Epi proColon, is a blood-based assay specifically developed for the early identification of colorectal cancer, distributed across the United States, Europe, and China. The company's portfolio further encompasses a blood test for hepatocellular carcinoma and Epi BiSKit, a pre-analytical solution providing reagents essential for preparing bisulfite-converted DNA. Epigenomics' research and development initiatives are focused on pinpointing relevant biomarkers in human tissue and subsequently creating and securing patents for associated in vitro diagnostic blood tests.
Aktienkurs
$0.83030862
Zuletzt synchronisiert: 2024-06-27
Marktkapitalisierung
$726.64K
Veränderung (1 Tag)
-1.35%
Veränderung (1 Jahr)
0.00%
Land
DE
Handel Epigenomics AG (ECX)

Kategorie

Dividendenrendite-Verlauf für Epigenomics AG (ECX)
Dividendenrendite (TTM) von Epigenomics AG (Aktienkürzel: ECX) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Epigenomics AG (ECX) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber